Back to today’s briefing

Story perspectives

Taiwan's CBL-514 Promises Major Fat Loss Breakthrough

7/29/2025

27 3

Summary

Story summary

Caliway Pharmaceuticals from Taiwan is making waves with CBL-514, an innovative injection designed to target and eliminate stubborn fat cells, particularly around the belly. In Phase 2b trials, over 75% of participants reported impressive fat loss. With Phase 3 trials on the horizon in 2025, hopes are high for FDA approval.

1 of 1

Story summary

Caliway Pharmaceuticals from Taiwan is making waves with CBL-514, an innovative injection designed to target and eliminate stubborn fat cells, particularly around the belly. In Phase 2b trials, over 75% of participants reported impressive fat loss. With Phase 3 trials on the horizon in 2025, hopes are high for FDA approval.